Inhibition of dengue virus RNA synthesis by an adenosine nucleoside

  • Antimicrob Agents Chemother. 2010 Jul;54(7):2932-9. doi: 10.1128/AAC.00140-10.
Yen-Liang Chen  1 ,  Zheng Yin ,  Jeyaraj Duraiswamy ,  Wouter Schul ,  Chin Chin Lim ,  Boping Liu ,  Hao Ying Xu ,  Min Qing ,  Andy Yip ,  Gang Wang ,  Wai Ling Chan ,  Hui Pen Tan ,  Melissa Lo ,  Sarah Liung ,  Ravinder Reddy Kondreddi ,  Ranga Rao ,  Helen Gu ,  Handan He ,  Thomas H Keller ,  Pei-Yong Shi
Affiliations
  • 1. Novartis Institute for Tropical Diseases, 10 Biopolis Road, No. 05-01 Chromos, 138670, Singapore.
Abstract

We recently reported that (2R,3R,4R,5R)-2-(4-amino-pyrrolo[2,3-d]pyrimidin-7-yl)-3-ethynyl-5-hydroxy-methyl-tetrahydro-furan-3,4-diol is a potent inhibitor of Dengue Virus (DENV), with 50% effective concentration (EC(50)) and cytotoxic concentration (CC(50)) values of 0.7 microM and >100 microM, respectively. Here we describe the synthesis, structure-activity relationship, and Antiviral characterization of the inhibitor. In an AG129 mouse model, a single-dose treatment of DENV-infected mice with the compound suppressed PEAK viremia and completely prevented death. Mode-of-action analysis using a DENV replicon indicated that the compound blocks viral RNA synthesis. Recombinant Adenosine Kinase could convert the compound to a monophosphate form. Suppression of host Adenosine Kinase, using a specific inhibitor (iodotubercidin) or small interfering RNA (siRNA), abolished or reduced the compound's Antiviral activity in Cell Culture. Studies of rats showed that (14)C-labeled compound was converted to mono-, di-, and triphosphate metabolites in vivo. Collectively, the results suggest that this Adenosine inhibitor is phosphorylated to an active (triphosphate) form which functions as a chain terminator for viral RNA synthesis.